Tyck till om SwePub Sök
här!
Sökning: L773:1573 7217
> Landberg Göran
> Stål Olle 1952 >
HER2 status in horm...
-
Rydén, LisaLund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Department of Surgery, Institution of Clinical Sciences, Lund University, Sweden
(författare)
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
- Artikel/kapitelEngelska2008
Förlag, utgivningsår, omfång ...
-
2007-07-18
-
Springer Science and Business Media LLC,2008
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-44443
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-44443URI
-
https://doi.org/10.1007/s10549-007-9660-2DOI
-
https://lup.lub.lu.se/record/540653URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BackgroundOverexpression of human epidermal growth factor receptor 2 (HER2) or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor (ER) positive disease. In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status.MethodsPremenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment. ER, progesterone receptor (PR) status and HER2 status was determined by immunohistochemistry using a tissue microarray. HER2 amplification was analysed by fluorescent in situ hybridisation and tumours being amplified and/or HER2 3+ were considered HER2+. HER2 status was evaluable in 83% of the patients and 12.6% were HER2+. In untreated patients, HER2 was a negative prognostic factor in ER+ patients, HR 2.95; 95% CI: 1.61–5.38, p < 0.001, but not in ER- patients, HR 0.67; 95% CI: 0.28–1.61, p = 0.4, and a significant interaction between the two markers was found, p < 0.01. HER2 status was not related to tamoxifen treatment efficacy in ER+ patients (term of interaction p = 0.95). When stratifying for PR status, similar results were achieved.DiscussionHER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours. The poor prognosis in HER2+ and ER+ patients may interfere with the interpretation of HER2 data in non-randomised trials of adjuvant tamoxifen.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Landberg, GöranLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups,Division of Pathology, Institution of Laboratory Medicine, Malmö University Hospital, Sweden(Swepub:lu)pat-gla
(författare)
-
Stål, Olle,1952-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)ollst87
(författare)
-
Nordenskjöld, Bo,1940-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)bono64
(författare)
-
Fernö, MårtenLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, Institition of Clinical Sciences, Lund University, Lund, Sweden(Swepub:lu)onk-mfe
(författare)
-
Bendahl, Pär-OlaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, Institition of Clinical Sciences, Lund University, Lund, Sweden(Swepub:lu)onk-pbe
(författare)
-
Kirurgi, LundSektion V
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Breast Cancer Research and Treatment: Springer Science and Business Media LLC109:2, s. 351-3570167-68061573-7217
Internetlänk
Hitta via bibliotek
Till lärosätets databas